Stephanie S. Okey M.S. has served on our board of directors since July 2019. For over 25 years, from 1986 until July 2015, Ms. Okey served in various positions of increasing responsibility in the biopharmaceutical industry, first at Bristol Myers Squib, then Genentech, Inc. for nearly 8 years, followed by 19 years at Genzyme, a Sanofi company. Ms. Okey’s management experience during her tenure at Genyzme included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases from August 2012 to July 2015 and as Vice President and General Manager, U.S. Genetic Diseases Business Unit from September 2011 to August 2012. Ms. Okey retired from Genzyme in July 2015. From June 2018 until March 2023, when it was acquired by Ipsen, Ms. Okey served as a member of the board of directors of Albireo Pharma, Inc., a Nasdaq-listed biopharmaceutical company and since December 2018, Ms. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company.
Since March 2021, Ms. Okey has served as a member of the board of directors of Orphazyme, a company based in Denmark. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University and a M.S. degree in Immunology and Medical Microbiology from Wright State University. Ms. Okey’s executive leadership experience in the life science industry and service on various biopharmaceutical company boards contributed to our board of directors’ conclusion that she should serve as a director of our company.
What is Stephanie Okey's net worth?
The estimated net worth of Stephanie Okey is at least $311,520.00 as of March 28th, 2024. Ms. Okey owns 6,000 shares of Crinetics Pharmaceuticals stock worth more than $311,520 as of October 1st. This net worth estimate does not reflect any other assets that Ms. Okey may own. Learn More about Stephanie Okey's net worth.
How do I contact Stephanie Okey?
Has Stephanie Okey been buying or selling shares of Crinetics Pharmaceuticals?
Stephanie Okey has not been actively trading shares of Crinetics Pharmaceuticals within the last three months. Most recently, Stephanie Okey sold 17,500 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $46.38, for a transaction totalling $811,650.00. Following the completion of the sale, the director now directly owns 6,000 shares of the company's stock, valued at $278,280. Learn More on Stephanie Okey's trading history.
Who are Crinetics Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Crinetics Pharmaceuticals?
During the last year, insiders at the sold shares 36 times. They sold a total of 761,755 shares worth more than $32,074,167.20. The most recent insider tranaction occured on September, 26th when CFO Marc Wilson sold 25,000 shares worth more than $1,277,750.00. Insiders at Crinetics Pharmaceuticals own 6.0% of the company.
Learn More about insider trades at Crinetics Pharmaceuticals. Information on this page was last updated on 9/26/2024.
